Search

Your search keyword '"Mignon F"' showing total 455 results
Start Over Author "Mignon F"

Refine your results

455 results on '"Mignon F"'

4. Long-Term Outcomes Among Participants in the WEGENT Trial of Remission-Maintenance Therapy for Granulomatosis With Polyangiitis (Wegenerʼs) or Microscopic Polyangiitis

Author

Puéchal, Xavier, Pagnoux, Christian, Perrodeau, Élodie, Hamidou, Mohamed, Boffa, Jean-Jacques, Kyndt, Xavier, Lifermann, François, Papo, Thomas, Merrien, Dominique, Smail, Amar, Delaval, Philippe, Hanrotel-Saliou, Catherine, Imbert, Bernard, Khouatra, Chahéra, Lambert, Marc, Leské, Charles, Ly, Kim H., Pertuiset, Edouard, Roblot, Pascal, Ruivard, Marc, Subra, Jean-François, Viallard, Jean-François, Terrier, Benjamin, Cohen, Pascal, Mouthon, Luc, Le Jeunne, Claire, Ravaud, Philippe, Guillevin, Loïc, Rispal, P., Baidi, N., Chrétien, O., Cevallos, R., Ducroix, J.-P., Darmaillacq, J.-G., Dubas, F., Maghakian, M.-N., Moreau, C., Dubos-Arvis, C., Frognier, R., Gobert, P., Pollini, J., Pingat, D., Janin-Manificat, L., Lafon, B., Kettaneh, A., Moiton, M., Ragnaud, J. M., Boudray, C., Raphanel, B., Renand, J.-P., Roux, M., Bonnaire, G., Guiso, A., André, J. M., Perrichot, R., Louvet, J., Artigues, N., Bienvenu, B., de Ligny, Hurault B., Le Hello, C., Letellier, P., Lobbedez, T., Ollivier, Y., Pujo, M., Ryckelynck, J.-P., Montseny, J.-J., Collet, P., Ayach, B., Dion, J.-J., Mouawad, H., Damade, R., Dupouët, L., Asgaraly, K., Depernet, B., Colin, T., Ioos, V., Rieu, V., Belmatoug, N., Foulon, L., Jebrak, G., du Coedic, L., Bachmeyer, C., Dumoulin, A., Godeau, B., Khellaf, M., Michel, M., Pastural, M., Schaeffer, A., Geffroy, M., Bielefeld, P., Fichet, D., Saraux, J.-L., Vinzio, S., Ehrlacher, P., Azria, A., Mariette, X., Tiab, M., Delansorne, D., Boullanger, N., Closs-Prophette, F., Goldstein, A., Bouscaud, L., Meunier, V., Hachulla, E., Hatron, P.-Y., Launay, D., Hottelart, C., Liozon, E., Longuet, O., Loustaud-Ratti, V., Soria, P., Vidal, E., Geffray, L., Henri, P., Landru, I., Guillemot, J.-M., Le Noach, J., Cordier, J.-F., Cottin, V., Gentil, B., Demolombe-Rague, S., Girard-Madoux, M.-H., Ninet, J., Pinède, L., Meynieux, J.-P., Serratrice, J., Xeridat, B., Bagnères, D., Roudier, J., Denis, B., Boillet, N., Geraads, A., Teyssandier, R., Degraeve, F., Le Quellec, A., Rivière, S., Rogé, C., Fauchay, J.-P., Wahl, D., Agard, C., Généreau, T., Meker, D., Bensakel, S., Vecina, F., Aubier, M., Foulon, G., Lelièvre, P., Lidove, O., Mignon, F., Meyer, O., Piperaud, M., Queffeulou, G., Vrtovsnik, F., Aouba, A., Arène, J.-P., Bérezné, A., Le Guern, V., Amoura, Z., Benveniste, O., Dimitri, D., Huong, Lê Thi D., Bergeron, A., Bourgarit, A., Farge, D., Mahr, A., Martinez, F., Séréni, D., Aslangul, E., Arnal, C., Cadranel, J., Daugas, E., Pelle, G., Rossert, J., Wislez, M., Gayraud, M., Bruet, A., Hillion, Y., Paccalin, M., Léone, J., Pennaforte, J.-L., Barbier, S., Legallicier, B., Dominique, S., Charasse, C., Coëtmeur, D., Duhamel, E., Goulias, J.-P., Bournerias, F., Gautherie, P., Schlienger, J.-L., Vidal, A., Diot, E., Diot, P., Vanhille, P., Bindi, P., and Cervantes, G.

Published
2016
Full Text
View/download PDF

9. Ferrofluid incorporation into a sol-gel matrix

Author

Madeira, Alexandra, Bée, Agnès, Maleki, Balaki, Kassouf, Mounir, Dupuis, Vincent, Dominique, Berling, Soppera, Olivier, Spangenberg, Arnaud, Royer, Francois, Gamet, Émilie, Damien, Jamon, Blanc-Mignon, F., Neveu, Sophie, PHysicochimie des Electrolytes et Nanosystèmes InterfaciauX (PHENIX), Institut de Chimie du CNRS (INC)-Sorbonne Université (SU)-Centre National de la Recherche Scientifique (CNRS), Université Pierre et Marie Curie - Paris 6 (UPMC)-Ecole Superieure de Physique et de Chimie Industrielles de la Ville de Paris (ESPCI Paris), Université Paris sciences et lettres (PSL)-Université Paris sciences et lettres (PSL)-Centre National de la Recherche Scientifique (CNRS)-Institut de Chimie du CNRS (INC), Institut de Science des Matériaux de Mulhouse (IS2M), Centre National de la Recherche Scientifique (CNRS)-Matériaux et nanosciences d'Alsace (FMNGE), Institut de Chimie du CNRS (INC)-Université de Strasbourg (UNISTRA)-Université de Haute-Alsace (UHA) Mulhouse - Colmar (Université de Haute-Alsace (UHA))-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-Institut de Chimie du CNRS (INC)-Université de Strasbourg (UNISTRA)-Université de Haute-Alsace (UHA) Mulhouse - Colmar (Université de Haute-Alsace (UHA))-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-Réseau nanophotonique et optique, Centre National de la Recherche Scientifique (CNRS)-Université de Strasbourg (UNISTRA)-Université de Haute-Alsace (UHA) Mulhouse - Colmar (Université de Haute-Alsace (UHA))-Centre National de la Recherche Scientifique (CNRS)-Université de Strasbourg (UNISTRA), Université de Haute-Alsace (UHA) Mulhouse - Colmar (Université de Haute-Alsace (UHA))-Centre National de la Recherche Scientifique (CNRS), Laboratoire Hubert Curien [Saint Etienne] (LHC), and Université Jean Monnet [Saint-Étienne] (UJM)-Centre National de la Recherche Scientifique (CNRS)-Institut d'Optique Graduate School (IOGS)

Subjects
[PHYS.PHYS.PHYS-OPTICS]Physics [physics]/Physics [physics]/Optics [physics.optics], [CHIM.INOR]Chemical Sciences/Inorganic chemistry, ComputingMilieux_MISCELLANEOUS
Abstract

International audience

Published
2019

12. Allergy to icodextrin

Author

Queffeulou, G, Lebrun-Vignes, B, Wheatley, P, Montagnac, R, and Mignon, F

Published
2000

13. Tolvaptan in Patients with Autosomal Dominant Polycystic Kidney Disease

Author

Torres VE, Chapman AB, Devuyst O, Gansevoort RT, Grantham JJ, Higashihara E, Perrone RD, Krasa HB, Ouyang J, Czerwiec FS, Tempo team, Gross P, Schulze B, Bichet D, Chauveau D, Peeters P, Voiculescu M, Manunta P, Tuazon J, Watnick T, Goral S, Horie S, Nutahara K, Torres V, Chapman A, Gansevoort R, Perrone R, Czerwiec F, Goldstein S, Cowley B, Fukagawa M, Torra R, Wei LJ, Cook T, Toto R, Agarwal R, August P, Bakris G, Beddhu S, Corwin H, Ruilope L, Rosa-Diez G, De La Fuente J, Martin R, Massari P, Novoa P, Rial M, Wasserman A, Faull R, Fraser I, Johnson D, Pedagagos E, Lian M, Pollock C, Cooper B, Rangan G, Russ G, McDonald S, Thomas M, Khoo D, Walker R, Pirson Y, Laecke V, Van der Niepen P, Sennesael J, Barre P, Alam A, Soroka S, Dieperink H, Strandgaard S, Petersen L, Berthoux F, Canaud B, Gontiers-Picard A, Huart A, Combe C, Delmas Y, Dussol B, Laville M, Guebre-Egziabher F, Mignon F, Michel C, Rieu P, Noel N, Ryckelynck J, Lobbedez T, Dellanna F, Kleophas W, Feldkamp T, Witzke O, Nurnberger J, Zeltner R, Walz G, Zeier M, Sommerer C, Bianchi S, Capasso G, Miranda N, Magistroni R, Bracale M, Remuzzi G, Rota S, Villa G, Tilocca P, Asahi K, Kato T, Endo M, Umezono T, Fujigaki Y, Kato A, Fukatsu A, Hasegawa H, Tayama Y, Hasegawa M, Hosoya T, Hanaoka K, Iehara N, Iino Y, Tsuruoka S, Imai E, Isaka Y, Ishimura E, Ito S, Sato H, Kamata K, Sakamoto H, Kamura K, Kusano E, Muto S, Kuwahara M, Matsubara A, Yorioka N, Mochizuki T, Narita I, Naya Y, Nihei N, Yukio N, Nishio S, Nitta K, Tsuchiya K, Okamura M, Sasaki S, Rai T, Seta K, Sugawara A, Shibazaki S, Sugiyama S, Tabei K, Takaichi K, Tomita K, Kitamura K, Tsukamoto Y, Tsuruya K, Nakano T, Ubara Y, Watanabe T, Yamamoto T, Yoshida K, Ishii D, Yuzawa Y, Meijer E, Vervloet M, Ciechanowski K, Wisniewska M, Gutowska-Jablonska M, Marcinkowska-Królewicz M, Klatko W, Wiśniewski T, Klinger M, Krajewska M, Ksiazek A, Orłowska G, Malecki R, Gontarek-Kacprzak J, Nowicki M, Makówka A, Rutkowski B, Wołyniec W, Rydzewski A, Sulowicz W, Jasik P, Covic A, Volovat C, Mircescu G, Petrescu L, Bobeica R, Barbarash O, Chesnokova L, Borovoy S, Demina L, Shostka G, Idovu M, Tkalich L, Geynits O, Tomilina N, Foggensteiner L, Holt S, Kingswood J, Lambie S, Peel R, MacDougall I, Tucker B, MacPhee I, Maxwell A, Brown H, Mikhail A, Bastin L, Turner N, Neary J, Wheeler D, Maxwell P, Wilkie M, Ong A, Zehnder D, Aldridge N, Adler S, Klein M, Battle D, Bennett W, Berger B, Dell K, Blumenfeld J, Donahue S, Bolin P, Browder R, Perry A, Oskoui F, Culpepper M, Dahl N, Edelstein C, Clegg L, Fischer D, Kaplan M, Kaveh K, Pankhaniya R, Koren M, Mansur K, Lafayette R, Lamar W, Lee J, Mahnensmith R, Nachman P, Mottl A, Miskulin D, Petersen J, Radhakrishnan J, Roppolo M, Basireddy M, Rosner M, Bolton W, Schulman G, Steed L, Steinman T, Hogan M, Venuto R, Turban S, Winklhofer F., Cardiovascular Centre (CVC), Groningen Kidney Center (GKC), Torres, Ve, Chapman, Ab, Devuyst, O, Gansevoort, Rt, Grantham, Jj, Higashihara, E, Perrone, Rd, Krasa, Hb, Ouyang, J, Czerwiec, F, Tempo, Team, Gross, P, Schulze, B, Bichet, D, Chauveau, D, Peeters, P, Voiculescu, M, Manunta, P, Tuazon, J, Watnick, T, Goral, S, Horie, S, Nutahara, K, Torres, V, Chapman, A, Gansevoort, R, Perrone, R, Goldstein, S, Cowley, B, Fukagawa, M, Torra, R, Wei, Lj, Cook, T, Toto, R, Agarwal, R, August, P, Bakris, G, Beddhu, S, Corwin, H, Ruilope, L, Rosa-Diez, G, De La Fuente, J, Martin, R, Massari, P, Novoa, P, Rial, M, Wasserman, A, Faull, R, Fraser, I, Johnson, D, Pedagagos, E, Lian, M, Pollock, C, Cooper, B, Rangan, G, Russ, G, Mcdonald, S, Thomas, M, Khoo, D, Walker, R, Pirson, Y, Laecke, V, Van der Niepen, P, Sennesael, J, Barre, P, Alam, A, Soroka, S, Dieperink, H, Strandgaard, S, Petersen, L, Berthoux, F, Canaud, B, Gontiers-Picard, A, Huart, A, Combe, C, Delmas, Y, Dussol, B, Laville, M, Guebre-Egziabher, F, Mignon, F, Michel, C, Rieu, P, Noel, N, Ryckelynck, J, Lobbedez, T, Dellanna, F, Kleophas, W, Feldkamp, T, Witzke, O, Nurnberger, J, Zeltner, R, Walz, G, Zeier, M, Sommerer, C, Bianchi, S, Capasso, G, Miranda, N, Magistroni, R, Bracale, M, Remuzzi, G, Rota, S, Villa, G, Tilocca, P, Asahi, K, Kato, T, Endo, M, Umezono, T, Fujigaki, Y, Kato, A, Fukatsu, A, Hasegawa, H, Tayama, Y, Hasegawa, M, Hosoya, T, Hanaoka, K, Iehara, N, Iino, Y, Tsuruoka, S, Imai, E, Isaka, Y, Ishimura, E, Ito, S, Sato, H, Kamata, K, Sakamoto, H, Kamura, K, Kusano, E, Muto, S, Kuwahara, M, Matsubara, A, Yorioka, N, Mochizuki, T, Narita, I, Naya, Y, Nihei, N, Yukio, N, Nishio, S, Nitta, K, Tsuchiya, K, Okamura, M, Sasaki, S, Rai, T, Seta, K, Sugawara, A, Shibazaki, S, Sugiyama, S, Tabei, K, Takaichi, K, Tomita, K, Kitamura, K, Tsukamoto, Y, Tsuruya, K, Nakano, T, Ubara, Y, Watanabe, T, Yamamoto, T, Yoshida, K, Ishii, D, Yuzawa, Y, Meijer, E, Vervloet, M, Ciechanowski, K, Wisniewska, M, Gutowska-Jablonska, M, Marcinkowska-Królewicz, M, Klatko, W, Wiśniewski, T, Klinger, M, Krajewska, M, Ksiazek, A, Orłowska, G, Malecki, R, Gontarek-Kacprzak, J, Nowicki, M, Makówka, A, Rutkowski, B, Wołyniec, W, Rydzewski, A, Sulowicz, W, Jasik, P, Covic, A, Volovat, C, Mircescu, G, Petrescu, L, Bobeica, R, Barbarash, O, Chesnokova, L, Borovoy, S, Demina, L, Shostka, G, Idovu, M, Tkalich, L, Geynits, O, Tomilina, N, Foggensteiner, L, Holt, S, Kingswood, J, Lambie, S, Peel, R, Macdougall, I, Tucker, B, Macphee, I, Maxwell, A, Brown, H, Mikhail, A, Bastin, L, Turner, N, Neary, J, Wheeler, D, Maxwell, P, Wilkie, M, Ong, A, Zehnder, D, Aldridge, N, Adler, S, Klein, M, Battle, D, Bennett, W, Berger, B, Dell, K, Blumenfeld, J, Donahue, S, Bolin, P, Browder, R, Perry, A, Oskoui, F, Culpepper, M, Dahl, N, Edelstein, C, Clegg, L, Fischer, D, Kaplan, M, Kaveh, K, Pankhaniya, R, Koren, M, Mansur, K, Lafayette, R, Lamar, W, Lee, J, Mahnensmith, R, Nachman, P, Mottl, A, Miskulin, D, Petersen, J, Radhakrishnan, J, Roppolo, M, Basireddy, M, Rosner, M, Bolton, W, Schulman, G, Steed, L, Steinman, T, Hogan, M, Venuto, R, Turban, S, Winklhofer, F., University of Zurich, Torres, Vicente E, Feldkamp, Thorsten (Beitragende*r), and Witzke, Oliver (Beitragende*r)

Subjects
Male, Tolvaptan, Medizin, 2700 General Medicine, SIROLIMUS, Kidney, V2 RECEPTOR ANTAGONIST, 10052 Institute of Physiology, Aquaretic, VASOPRESSIN V-2-RECEPTOR ANTAGONIST, Polycystic Kidney, 10035 Clinic for Nephrology, Medicine (all), General Medicine, Organ Size, Middle Aged, Adolescent, Adult, Benzazepines, Double-Blind Method, Female, Glomerular Filtration Rate, Humans, Polycystic Kidney, Autosomal Dominant, Sodium, Young Adult, Antidiuretic Hormone Receptor Antagonists, LONG-ACTING SOMATOSTATIN, Autosomal Dominant, 10076 Center for Integrative Human Physiology, OPC-41061, medicine.symptom, medicine.drug, medicine.medical_specialty, RENAL-FUNCTION, CYST GROWTH, Autosomal dominant polycystic kidney disease, Urology, Renal function, Kidney Volume, 610 Medicine & health, Placebo, Article, VOLUME PROGRESSION, Cystic kidney disease, Internal medicine, medicine, HYPONATREMIA, business.industry, urogenital system, ORAL TOLVAPTAN, medicine.disease, Endocrinology, Albuminuria, 570 Life sciences, biology, business
Abstract

BACKGROUND: The course of autosomal dominant polycystic kidney disease (ADPKD) is often associated with pain, hypertension, and kidney failure. Preclinical studies indicated that vasopressin V 2 -receptor antagonists inhibit cyst growth and slow the decline of kidney function. METHODS: In this phase 3, multicenter, double-blind, placebo-controlled, 3-year trial, we randomly assigned 1445 patients, 18 to 50 years of age, who had ADPKD with a total kidney volume of 750 ml or more and an estimated creatinine clearance of 60 ml per minute or more, in a 2:1 ratio to receive tolvaptan, a V 2 -receptor antagonist, at the highest of three twice-daily dose regimens that the patient found tolerable, or placebo. The primary outcome was the annual rate of change in the total kidney volume. Sequential secondary end points included a composite of time to clinical progression (defined as worsening kidney function, kidney pain, hypertension, and albuminuria) and rate of kidney-function decline. RESULTS: Over a 3-year period, the increase in total kidney volume in the tolvaptan group was 2.8% per year (95% confidence interval [CI], 2.5 to 3.1), versus 5.5% per year in the placebo group (95% CI, 5.1 to 6.0; P

Published
2012

15. Pharmacokinetics of rilmenidine in patients with chronic renal insufficiency and in hemodialysis patients

Author

Aparicio, A., Dratwa, M., Esper, N. El, Fillastre, J.P., Levaltier, B., Lins, R., Meyrier, A., Mignon, F., Ryckelnyck, J.P., and Sennesael, J.

Subjects
Rilmenidine -- Physiological aspects, Chronic kidney failure -- Drug therapy, Hemodialysis patients -- Health aspects, Health
Abstract

The pharmacokinetics of rilmenidine (1 mg orally) was studied in 3 groups of patients with stable chronic renal insufficiency. This was an open, single-blind study following a single administration, and after 15 days of treatment. Group 1 included 11 patients with a creatinine clearance between 15 and 80 mL/min. Group 2 included 17 patients with a creatinine clearance

Published
1994

19. Using the Targeted Solutions Tool® to Improve Emergency Department Handoffs in a Community Hospital

Author

Mignon F. Benjamin, Klaus Nether, and Sarah Hargrave

Subjects
Leadership and Management, Handoff communication, Hospitals, Community, 03 medical and health sciences, 0302 clinical medicine, Clinical Protocols, Health care, Medicine, Electronic Health Records, Humans, 030212 general & internal medicine, business.industry, Communication, Trauma center, Patient Handoff, 030208 emergency & critical care medicine, Emergency department, medicine.disease, Quality Improvement, Community hospital, Handover, Medical emergency, business, Telecommunications, Emergency Service, Hospital, Private physician
Abstract

Article-at-a-Glance Background There is little evidence for solutions to improve the handoff process between units, particularly from the emergency department (ED) to the inpatient unit. A systematic approach was used to improve the handoff communication process between the ED and the four private physician groups serving Juneau, Alaska, that admit and deliver care to patients of a 73-bed, Level 4 trauma center community hospital. Methods Data were collected in using the Joint Commission Center for Transforming Healthcare's Targeted Solutions Tool® (TST®) to determine the rate of defective handoff communications and the factors that contributed to those defective handoff communications. Targeted solutions were then implemented to specifically address the identified contributing factors. Results A random sample of 107 handoff opportunities was collected during the baseline phase (November 4, 2011–January 12, 2012) to measure performance and identify the contributing factors that led to defective handoffs. The baseline handoff communications defective rate was 29.9% (32 defective handoffs/107 handoff opportunities). The top four contributing factors, together accounting for 69.8% of all the causes of defective handoffs, were inaccurate/incomplete information, method ineffective, no standardized procedures for an effective handoff, and the person initiating the handoff, known as the "sender," lacks knowledge about the patient. After implementation of targeted solutions to the identified contributing factors, the handoff communications defective rate for the "improve" phase (April 1, 2012–July 29, 2012) was reduced from baseline by 58.2% to 12.5% (13 defective handoffs/104 handoff opportunities), p = 0.002; 2-proportions test). The number of adverse events related to handoff communications declined as the handoff communications defective rate improved. Conclusion Use of the TST was associated with improvement in the ED handoff communication process.

Published
2016

23. Miss Dimple Disappears : A Mystery

Author

Mignon F. Ballard and Mignon F. Ballard

Abstract

It's 1942, almost a year since the Japanese bombed Pearl Harbor, and the residents of the small town of Elderberry, Georgia, have been rattled down to their worn, rationed shoes. For young teacher Charlie Carr, life and love aren't going exactly as planned—her head dictates loyalty to the handsome corpsman, Hugh, but whenever she thinks of her best friend's beau, Will, her heart does the Jersey Bounce. Charlie is doubly troubled by the disappearance of beloved schoolmistress Miss Dimple Kilpatrick one frosty November morning just before Thanksgiving. Miss Dimple, who has taught the town's first graders—including Charlie—for almost forty years, would never just skip town in the middle of the school year, and Charlie and her best friend, Annie, are determined to prove it.

Published
2010

27. CKD ANAEMIA

Author

Fernandes, J., primary, Ribeiro, S., additional, Garrido, P., additional, Sereno, J., additional, Costa, E., additional, Reis, F., additional, Santos-Silva, A., additional, Hirata, M., additional, Tashiro, Y., additional, Aizawa, K., additional, Endo, K., additional, Fujimori, A., additional, Morikami, Y., additional, Okada, S., additional, Kumei, M., additional, Mizobuchi, N., additional, Sakai, M., additional, Claes, K., additional, Di Giulio, S., additional, Galle, J., additional, Guerin, A., additional, Kiss, I., additional, Suranyi, M., additional, Winearls, C., additional, Wirnsberger, G., additional, Farouk, M., additional, Manamley, N., additional, Addison, J., additional, Herlitz, H., additional, Visciano, B., additional, Nazzaro, P., additional, Riccio, E., additional, Del Rio, A., additional, Mozzillo, G. R., additional, Pisani, A., additional, Gupta, A., additional, Ikizler, T. A., additional, Lin, V., additional, Guss, C., additional, Pratt, R. D., additional, Stewart, V. M., additional, Anthoney, A., additional, Blenkin, S., additional, Ahmed, S., additional, Yasumoto, M., additional, Tsuda, A., additional, Ishimura, E., additional, Ohno, Y., additional, Ichii, M., additional, Nakatani, S., additional, Mori, K., additional, Fukumoto, S., additional, Uchida, J., additional, Emoto, M., additional, Nakatani, T., additional, Inaba, M., additional, Joki, N., additional, Tanaka, Y., additional, Kubo, S., additional, Asakawa, T., additional, Hase, H., additional, Ikeda, M., additional, Inaguma, D., additional, Sakaguchi, T., additional, Shinoda, T., additional, Koiwa, F., additional, Negi, S., additional, Yamaka, T., additional, Shigematsu, T., additional, Suranyi, M. G., additional, Groenendaal-Van De Meent, D., additional, Den Adel, M., additional, Rijnders, S., additional, Essers, H., additional, Golor, G., additional, Haffner, S., additional, Schaddelee, M., additional, Yogo, K., additional, Choukroun, G., additional, Hannedouche, T., additional, Kessler, M., additional, Laville, M., additional, Levannier, M., additional, Mignon, F., additional, Rostaing, L., additional, Rottembourg, J., additional, Jeon, J., additional, Park, Y., additional, Karanth, S., additional, Prabhu, R., additional, Bairy, M., additional, Nagaraju, S. P., additional, Bhat, A., additional, Kosuru, S., additional, Parthasarathy, R., additional, Kamath, S., additional, Prasad, H. K., additional, Kallurwar, K. P., additional, Nishida, H., additional, Iimori, S., additional, Okado, T., additional, Rai, T., additional, Uchida, S., additional, Sasaki, S., additional, Wan, Q., additional, Cana Ruiu, D. C., additional, Ashcroft, R., additional, Brown, C., additional, Williams, J., additional, and Mikhail, A., additional

Published
2014
Full Text
View/download PDF

28. [Antibodies against human recombinant erythropoietin: an unusual cause of erythropoietin resistance]

Author

Virón B, Kolta A, Jean-Jacques Kiladjian, Mignon F, Mayeux P, and Casadevall N

Subjects
Erythroid Precursor Cells, Male, Drug Resistance, Granulocyte-Macrophage Colony-Stimulating Factor, Anemia, Hematemesis, Combined Modality Therapy, Recombinant Proteins, Angiodysplasia, Melena, Bone Marrow, Isoantibodies, Renal Dialysis, Immunoglobulin G, Tumor Cells, Cultured, Humans, Kidney Failure, Chronic, Blood Transfusion, Leukemia, Erythroblastic, Acute, Digestive System, Erythropoietin, Cell Division, Aged
Abstract

In a 70 year old man with primary glomerulonephritis, severe anemia occurred after 4 years on hemodialysis and rHu-EPO. The usual mechanisms of EPO-resistance were excluded. A bone marrow sample showed red all aplasia. No circulating EPO could be detected; the serum inhibited the growth of erythroid precursors in bone marrow cultures. Immunoprecipitation identified an IgG anti-EPO, still active against deglycosylated EPO, i.e. directed against the peptidic matrix. Its high neutralising capacity and the absence of any immune abnormality rule out an auto-antibody. Anti-rHu EPO immunisation is a very rare occurrence, made severe by transfusion-dependence and the risk of hemosiderosis. An immuno-modulating treatment can therefore be justified.

Published
2002

31. [Sclerosing peritonitis. A series of 10 cases and review of the literature]

Author

Carbonnel, F., Barrié, F., Beaugerie, L., Houry, S., Chatelet, F., Gallot, D., Malafosse, M., Guerre, J., Mignon, F., Cosnes, J., Agents pathogènes et inflammation - UFC (EA 4266) (API), Université de Franche-Comté (UFC), Université Bourgogne Franche-Comté [COMUE] (UBFC)-Université Bourgogne Franche-Comté [COMUE] (UBFC), Université Pierre et Marie Curie - Paris 6 (UPMC), Institut de Physique Nucléaire d'Orsay (IPNO), Centre National de la Recherche Scientifique (CNRS)-Institut National de Physique Nucléaire et de Physique des Particules du CNRS (IN2P3)-Université Paris-Sud - Paris 11 (UP11), Université Paris-Sud - Paris 11 (UP11)-Institut National de Physique Nucléaire et de Physique des Particules du CNRS (IN2P3)-Centre National de la Recherche Scientifique (CNRS), and Perron, Nicolas

Subjects
Adult, Liver Cirrhosis, Male, Sclerosis, [CHIM.ORGA]Chemical Sciences/Organic chemistry, Middle Aged, Peritonitis, [CHIM.ORGA] Chemical Sciences/Organic chemistry, Diverticulitis, Colonic, Radiography, Fatal Outcome, Peritoneal Dialysis, Continuous Ambulatory, Antineoplastic Combined Chemotherapy Protocols, Humans, Female, Infusions, Parenteral, Peritoneum, Intestinal Obstruction, Aged, Retrospective Studies
Abstract

International audience; OBJECTIVE AND METHODS: The aim of this study was to describe the main features of sclerosing peritonitis, using a retrospective study in 10 patients. RESULTS: The main causes of sclerosing peritonitis were continual ambulatory peritoneal dialysis (n = 3), peritoneal chemotherapy (n = 2) and liver cirrhosis (n = 2). Sclerosing peritonitis was revealed by acute or chronic bowel obstruction (n = 8). Small bowel X-rays and abdominal tomodensitometry showed a small bowel dilatation with a normal mucosa (n = 7), ascites (n = 5) as well as agglutination and fixation of small bowel loops within a cocoon (n = 3). Surgical viscerolysis was performed in 9 patients and allowed prolonged clinical remission in 4; 3 patients died postoperatively (1 had a cirrhosis and 2 were treated with continuous ambulatory peritoneal dialysis), 1 patient had a complicated postoperative course with recurrent enterocutaneous fistulae. CONCLUSION: Sclerosing peritonitis may be suspected in a patient who presents a combination of bowel obstruction, small bowel dilatation without mucosal disease and ascites. Surgical viscerolysis is a dangerous operation associated with high mortality in patients with renal failure or cirrhosis.

Published
1995

33. Randomised controlled trial of enalapril and beta blockers in non-diabetic chronic renal failure

Author

Hannedouche, T., Landais, P., Goldfarb, B., el Esper, N., Fournier, A., Godin, M., Durand, D., Chanard, J., Mignon, F., and Suo, J. M.

Subjects
urologic and male genital diseases, Research Article
Abstract

OBJECTIVE--To compare the ability of angiotensin converting enzyme inhibitors and beta blockers to slow the development of end stage renal failure in non-diabetic patients with chronic renal failure. DESIGN--Open randomised multicentre trial with three year follow up. SETTING--Outpatient departments of six French hospitals. PATIENTS--100 hypertensive patients with chronic renal failure (initial serum creatinine 200-400 mumol/l. 52 randomised to enalapril and 48 to beta blockers (conventional treatment). INTERVENTIONS--Enalapril or beta blocker was combined with frusemide and, if necessary, a calcium blocker or centrally acting drug in patients whose diastolic pressure remained above 90 mm Hg. RESULTS--17 patients receiving conventional treatment and 10 receiving enalapril developed end stage renal failure. The cumulative renal survival rate was significantly better in the enalapril group than in the conventional group (P < 0.05). The slope of the reciprocal serum creatinine concentration was steeper in the conventionally treated patients (-6.89 x 10(-5)l/mumol/month) than in the enalapril group (-4.17 x 10(-5)l/mumol/month; P < 0.05). No difference in blood pressure was found between groups. CONCLUSION--In hypertensive patients with chronic renal failure enalapril slows progression towards end stage renal failure compared with beta blockers. This effect was probably not mediated through controlling blood pressure.

Published
1994

Catalog

Books, media, physical & digital resources
See catalog results